Ulcerative Colitis

Harvey's not sure if he's on the real thing or a placebo - but either way, he says being in the study has already helped.

Harvey Ottinger, memory loss survivor: "I take extra precautions, like writing down certain things that I have to do.

I feel good, yeah." And if he does forget something, Kay is right by his side to remind him.

Researchers say nicotine does not pose any safety concerns and is only addictive when it's combined with tobacco.

Nicotine patches may not be a practical treatment for long-term use, so drugs are being developed that mimic what it does in the brain.

Video On Demand: Build Your Own Newscast Copyright 2006, ABC7/KGO-TV/DT.

ABC7 News TeamDr.

Dean Edell, Medical ReporterRELATED: Dr.'s BIO Print story Email Friend E-Mail story Newsletters RSS More Stories Today's Headlines Man Named In CHP Impersonation Case Hwy 85 Re-Opens Following Hazardous Spill Richmond Girl Struck By Stray Bullet archive ABC7 Sidebar: For More Information, Contact: Jennifer Nachburn University of Vermont 86 S.

Williams Str...

UNI SD RA VC1935 Other Business Related NewsU.S.

stocks mixed on inflation newsCBI uncovers extensive network engaged in IPO scamPakistan for building trade, energy corridor for China World Bank team to aid Bihar food supplyU.S.

stocks open higher as core CPI matches viewD.Boerse sets sights on pan-European stock marketGold drifts lower in Europe, trades in narrow rangeGLOBAL MARKETS-U.S.

inflation data boosts bond futures, sharesBaxter International donates doses to IHPCall rates end flat at 6.90-7.00 pc, bond prices fallTata Coffee enters into hospitality sectorKemwell clinches Pfizer's Swedish manufacturing unitU.S.

real earnings fall in JanuaryU.S.

minority foreclosures are risingCPI rises in January much as expectedAnother Doha round of talks...

About IMS IMS is a novel analogue of inosine, an endogenous purine and a natural by-product of adenosine metabolism.

Inotek discovered the unique, anti-inflammatory properties of inosine although inosine, itself, is not a candidate for drug development due to its rapid metabolism.

IMS was specifically developed to both take advantage of the anti-inflammatory properties of inosine and to avoid its metabolic pathway.

In this regard, IMS represents a potentially exciting and novel approach to inflammatory bowel disease and many other chronic inflammatory conditions.

About Inotek Pharmaceuticals Inotek Pharmaceuticals Corporation (www.inotekcorp.com) is a private, high-growth, development-stage pharmaceutical company.

Inotek has two products in clinical development and five other products in pre-clinical development targeting oncology, cardiovascular, and inflammatory diseases.

The Company is pursuing indications in hospital cardiovascular markets as well as specialty care markets including dermatology, gastroenterology and oncology.

All of Inotek's technologies were discovered and developed by Inotek researchers.

The Company currently has approximately 120 employees, based in its headquarters and main laboratories in Beverly, Massachusetts and its clinical operations and GMP manufacturing facilities in Israel.

The Company's other lead clinical program is focused on the development of pot...